Last year, FDA approved 11 new drugs and biologics as well as 30 supplemental indications and four biosimilars, according to commentary by FDA officials published in Nature Reviews.
New research led by Friends of Cancer Research demonstrates that decreases in circulating tumor DNA after initiation of treatment are associated with improved overall survival in patients with advanced non-small cell lung cancer treated with immunotherapy or chemotherapy.
